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Purpose: To evaluate and compare the cellular effects of four commercially available anti-inflammatory eye drops and
their active components on human corneal epithelial cells (HCECs) in vitro.
Methods: The cellular effects of four eye drops (Bromfenac Sodium Hydrate Eye Drops, Pranoprofen Eye Drops,
Diclofenac Sodium Eye Drops, and Tobramycin & Dex Eye Drops) and their corresponding active components were
evaluated in an HCEC line with five in vitro assays. Cell proliferation and migration were measured using 3-(4,5)-
dimethylthiahiazo (-z-y1)-3 5-di-phenytetrazoliumromide (MTT) assay and transwell migration assay. Cell damage was
determined with the lactate dehydrogenase (LDH) assay. Cell viability and median lethal time (LT50) were measured by
7-amino-actinomycin D (7-AAD) staining and flow cytometry analysis.
Results: Cellular effects after exposure of HCECs to the four anti-inflammatory eye drops were concentration dependent.
The differences of cellular toxicity on cell proliferation became significant at lower concentrations (<0.002%). Diclofenac
Sodium Eye Drops showed significant increasing effects on cell damage and viability when compared with the other three
solutions. Tobramycin & Dex Eye Drops inhibited the migration of HCECs significantly. Tobramycin & Dex Eye Drops
showed the quickest effect on cell viability: the LT50 was 3.28, 9.23, 10.38, and 23.80 min for Tobramycin & Dex Eye
Drops, Diclofenac Sodium Eye Drops, Pranoprofen Eye Drops, and Bromfenac Sodium Hydrate Eye Drops, respectively.
However, the comparisons of cellular toxicity revealed significant differences between the eye drops and their active
components under the same concentration. The corneal epithelial toxicity differences among the active components of
the four eye drops became significant as higher concentration (>0.020%).
Conclusions: The four anti-inflammatory eye drops showed different cellular effects on HCECs, and the toxicity was not
related with their active components, which provides new reference for the clinical application and drug research and
development.
Anti-inflammatory  agents  have  been  widely  used
systemically  and  topically  in  the  treatment  of  ocular
inflammatory  conditions  following  cataract  surgery  and
glaucoma surgery [1]. Ophthalmic corticosteroids have been
the first-line therapy to reduce the postoperative inflammation
by  inhibition  of  phospholipase  A2  production.  However,
topical  corticosteroid  application  may  lead  to  impaired
corneal  wound  healing,  cataract  formation,  glaucoma  by
elevated  intraocular  pressure  (IOP),  and  increased  risk  of
infection  [2].  Non-steroidal  anti-inflammatory  drugs
(NSAIDs) exert an equivalent anti-inflammatory effect by
inhibiting  cyclooxygenases  (COXs)  that  mediate  the
breakdown of arachidonic acid to produce prostaglandins and
other metabolic products in the arachidonic acid cascade, and
diclofenac sodium can also interfere with the lipoxygenase
pathway [3]. Moreover, these drugs have shown an increasing
use in managing posttraumatic or postoperative pain because
of  their  analgesic  effects,  and  they  treat  allergic  ocular
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disorders  by  inhibiting  prostaglandin  synthesis  [4,5].
Compared with corticosteroids, NSAIDs have become widely
accepted to control ocular inflammation and pain because they
do  not  raise  IOP  and  they  reduce  the  risk  of  secondary
cataracts or infections [6].
Although the complications of NSAIDs are considerably
less  frequent  than  those  of  corticosteroids,  some  reports
describe the adverse effects from topical NSAIDs, especially
on conditions such as autoimmune disease or dry eyes. The
most  commonly  reported  adverse  effects  from  topical
NSAIDs  include  stinging,  irritation,  superficial  punctate
keratitis,  corneal  infiltrates,  and  melting  [7].  In  addition,
NSAIDs inhibit COX activity in the arachidonic acid cascade
and  decrease  prostaglandin  synthesis.  Prostaglandins  are
essential for protein and DNA synthesis in the epidermal cells;
therefore, postoperative use of NSAIDs (especially diclofenac
sodium) may affect corneal epithelial wound healing [3,8]. As
reported previously, diclofenac sodium significantly delays
early wound healing in the scraped rabbit corneal epithelium
and re-epithelialization after penetrating keratoplasty [8].
Although a few articles have compared the effects of
these  anti-inflammatory  eye  drops  on  the  proliferation  or
migration of corneal epithelial cells or conjunctival epithelial
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3147cells  [9],  little  is  known  about  the  acute  or  early  corneal
cytotoxicity and the toxicity of their active components. In the
present study, we systemically compared the cellular effects
of three NSAIDs (Bromfenac Sodium Hydrate Eye Drops,
Pranoprofen Eye Drops, and Diclofenac Sodium Eye Drops)
and  one  corticosteroid  solution  (Tobramycin  &  Dex  Eye
Drops)  and  their  corresponding  active  components  on
immortalized  human  corneal  epithelial  cells  (HCECs)  by
using five in vitro assays, including 3-(4,5)-dimethylthiahiazo
(-z-y1)-3  5-di-phenytetrazoliumromide  (MTT)  assay,
transwell  migration  assay,  lactate  dehydrogenase  (LDH)
assay, 7-amino-actinomycin D (7-AAD) staining and flow
cytometry analysis. We found that the four anti-inflammatory
eye drops showed different cellular effects on HCECs, and the
toxicity was not related with their active components, which
provides new reference for the clinical application and drug
research and development.
METHODS
Eye drops: Senju Pharmaceutical Co.,Ltd. (Osaka, Japan)
provided the four anti-inflammatory eye drops and their active
components  for  this  study,  including  three  NSAIDs
(Bromfenac Sodium Hydrate Eye Drops, Pranoprofen Eye
Drops,  and  Diclofenac  Sodium  Eye  Drops)  and  one
corticosteroid (Tobramycin & Dex Eye Drops). The active
components of the four eye drops were dissolved in DMEM/
F-12  (Invitrogen,  Carlsbad,  CA)  media  as  the  same
concentration as that of the commercial solutions. Table 1 lists
the main information of the four anti-inflammatory eye drops.
Human  corneal  epithelial  cell  culture:  Simian  virus  40–
immortalized HCECs were provided by Choun-Ki Joo (The
Catholic University of Korea, School of Medicine, Seoul,
Korea). The cells were cultured in DMEM/F-12 (1:1) media,
5% fetal bovine serum (FBS; Gibco-BRL, Grand Island, NY),
5 μg/ml insulin (Sigma, St. Louis, MO), 0.1 ng/ml cholera
toxin (EMD Biosciences, San Diego, CA), 10 ng/ml human
epidermal growth factor (hEGF; R&D Systems, Minneapolis,
MN),  and  0.5%  dimethyl  sulfoxide  (DMSO;  Sigma)  in  a
humidified 5% CO2 incubator at 37 °C [10].
Cell  proliferation  assay:  Cell  proliferation  was  measured
using MTT assay. Briefly, HCECs were inoculated 3,000 cells
per well in 96-well plates and allowed to adhere. The media
were aspirated and replaced with the media containing drugs
with different dilutions for 24 h, followed by 4-h incubation
with MTT. The MTT transformed crystals were dissolved in
DMSO, and absorbance at 490 nm was measured using a
microplate  reader  (SpectraMax  M2,  Molecular  Devices,
Menlo Park, CA).
Cell migration assay: Migration assay was performed on a
6.5-mm-diameter transwell chamber with an 8-μm pore size
(Corning Costar, Cambridge, MA). HCECs (5×104 cells) in
the serum-free DMEM/F-12 media were inoculated on the top
of  the  transwell  chamber  and  allowed  to  migrate  toward
DMEM/F-12 medium containing 1% FBS supplemented with
different drugs. Following 15 h incubation, the cells on the
upper surface of the membranes were removed with cotton
swabs, and the cells at the bottom of the filter were fixed with
100% ethanol for 10 min and stained with 0.1% crystal violet
solution for 30 min. The dye was eluted using 33% acetic acid,
and crystal violet absorbance was measured at 570 nm using
the microplate reader.
Cell  damage  measurement:  Early  cell  damage  was
determined  using  the  LDH  cytotoxicity  detection  kit
(Promega, Madison, WI), which quantifies the LDH release
from the cells into the culture medium. The HCECs were
seeded 5,000 cells per well in 96-well plates for 24 h to
promote adherence. The cells were treated as the same as the
evaluation of cell proliferation. Cell-free supernatants from
the cultures were collected, passed through a 0.2-µm filter,
and used in the LDH assay as instructed by the manufacturer.
Maximum LDH release (high control) was determined by
solubilizing cells with 1% Triton X-100, and spontaneous
LDH release (low control) was determined by incubating cells
with the medium alone. A reduction reaction of tetrazolium
salt (INT) to a red formazan salt was used as an indicator of
LDH activity in the supernatant. Absorbance was read at 490
nm by using a microplate reader. Results were quantified as
(experimental value - low control/high control - low control)
× 100.
Cell viability detection: HCECs were seeded for 24 h and then
incubated with different drugs for another 24 h. Next, the cells
were collected by centrifugation and incubated by 7-AAD
staining  (1  µg/ml  final  concentration;  7-AAD;  BD
PharMingen,  San  Diego,  CA).  Cell  mortality  rate  was
measured using flow cytometry.
Median lethal time assay: HCECs (3×105 cells) were collected
and  treated  with  100-μl  undiluted  anti-inflammatory  eye
TABLE 1. ANTI-INFLAMMATORY EYE DROPS USED IN THE PRESENT STUDY.
Generic name Active component Preservative pH
Bromfenac Sodium Hydrate Eye Drops (Senju, Japan) Bromfenac sodium hydrate (0.1%) 0.005% BAC* 7.5–8.5
Pranoprofen Eye Drops (Senju, Japan) Pranoprofen (0.1%) 0.007% BAC* 7.5–8.5
Diclofenac Sodium Eye Drops (Sinqi, China) Diclofenac sodium (0.1%) NK† 7.0–8.5
Tobramycin & Dex Eye Drops (Alcon, USA) Tobramycin (0.3%) & Dex (0.1%) 0.001% BAC* 5.3‡
               *BAC: Benzalkonium chloride; †NK: not known; ‡: measured result.
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3148drops for different exposure times. The treatment was stopped
by 10-ml DMEM/F-12 media containing 10% FBS. The cells
were then labeled by 7-AAD staining, and the cell viability
was  measured  using  flow  cytometry.  Median  lethal  time
(LT50, time when the mortality rate was 50%) was counted
according to the cell viability curve.
Figure 1. Effects of the four anti-inflammatory eye drops on the proliferation of cultured HCECs. HCECs were treated with 0.001%, 0.002%,
and 0.010% eye drops for 24 h (n=4) and analyzed by morphological observation (A) and MTT assay (B). The inhibitory effects of the four
eye drops were in a concentration-dependent manner, and the differences among the four solutions became less significant as the concentrations
increased. All the experiment groups showed a significant inhibitory effect when compared with the control except for the Pranoprofen Eye
Drops and Bromfenac Sodium Hydrate Eye Drops at the 0.001% concentration.
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3149Statistical analysis: Data are presented as mean±SD. The
differences were analyzed by SPSS 10.0 (SPSS Inc., Chicago,
IL) software (one-way ANOVA) with a significance value of
p<0.05.
Figure 2. Influence of the four anti-inflammatory eye drops on the migration of cultured HCECs. HCECs were inoculated on the top of the
transwell chamber and were induced to migrate toward the lower chambers containing the 0.001% eye drops and 1% FBS for 15 h (n=4). The
transmigrated HCECs were stained with crystal violet and visualized with a microscope (A). The dye was eluted with acetic acid, and the
crystal violet absorbance was measured (B). Only Tobramycin & Dex Eye Drops showed a significant difference compared with the control
at the concentration.
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3150RESULTS
Comparisons  of  corneal  epithelial  effects  among  anti-
inflammatory eye drops: To evaluate the cellular effects of the
four anti-inflammatory eye drops on HCECs, five assays were
used in the present study. Acute cytotoxicity was evaluated
by the measurement of median lethal time, chronic cellular
effects were evaluated by the cell proliferation, migration,
damage, and cell viability assay, in which corneal epithelial
cells were treated with individual eye drops for 15 or 24 h.
The effects on the proliferation of cultured HCECs were
evaluated  with  MTT  assay.  HCECs  were  incubated  with
0.001% (100 fold dilution), 0.002% (50 fold dilution), and
0.010% (10-fold dilution) eye drops for 24 h. The proliferation
inhibition  of  the  four  eye  drops  was  in  a  concentration-
dependent  manner,  and  the  differences  among  the  four
solutions  became  less  significant  as  the  concentrations
increased. All the experiment groups showed a significant
inhibitory effect when compared with the control except for
the Pranoprofen Eye Drops and Bromfenac Sodium Hydrate
Eye  Drops  at  the  0.001%  concentration;  there  were  no
differences between these two groups (Figure 1A,B).
Cell migration plays an important role in corneal wound
healing. We used the transwell migration assay to quantify the
effects of eye drops (0.001%) on the migration of cultured
HCECs. The transmigrated cells were stained with crystal
violet  (Figure  2A)  and  the  absorbance  of  elution  was
measured.  There  was  no  significant  influence  on  HCEC
migration compared with the control, except for Tobramycin
& Dex Eye Drops (Figure 2B).
Figure  3.  Effects  of  the  four  anti-
inflammatory eye drops on cell damage
of  cultured  HCECs.  HCECs  were
treated  with  0.001%,  0.002%,  and
0.010% eye drops for 24 h (n=4). Cell
supernatants  were  collected  and
detected by LDH assay. LDH release
after exposure of cells to the eye drops
was  concentration  dependent.
Diclofenac Sodium Eye Drops showed
the most significant toxicity among the
four eye drops at the three concentration
groups.  At  the  higher  0.010%
concentration, all four eye drops caused
apparent  cell  damage  and  LDH
releasing,  and  the  differences  among
them became less significant.
Figure  4.  Effects  of  the  four  anti-
inflammatory eye drops on the viability
of  cultured  HCECs.  HCECs  were
treated with 0.001% eye drops for 24 h
(n=4). The cells were stained with 7-
AAD, and cell mortality was analyzed
using flow cytometry. All four eye drops
showed  significant  effects  on  the
viability  of  HCECs,  and  Diclofenac
Sodium  Eye  Drops  showed  the  most
significant toxicity among the four eye
drops.
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3151Cellular toxicity always causes membrane damage and
results  in the  releasing  of  LDH  from  the  cytoplasma.  By
detecting the LDH in cell supernatant with 0.001%, 0.002%,
and 0.010% eye drops, we found that Diclofenac Sodium Eye
Drops showed the most significant toxicity among the four
solutions at three concentration groups. At the higher 0.010%
concentration, all four solutions caused apparent cell damage,
LDH releasing, and the differences among them became less
significant (Figure 3). The results were basically identical
with the measurement of cell mortality by 7-AAD staining at
the 0.001% concentration (Figure 4). The number of dead cells
treated with Diclofenac Sodium Eye Drops showed almost 3–
5 folds of the cells treated with the other three solutions.
Acute cytotoxicity was detected by treating the HCECs
with  the  original  eye  drops.  The  LT50  of  the  four  anti-
inflammatory  eye  drops  was  23.80  min  for  Bromfenac
Sodium Hydrate Eye Drops, 10.38 min for Pranoprofen Eye
Drops, 9.23 min for Diclofenac Sodium Eye Drops, and 3.28
min for Tobramycin & Dex Eye Drops (Figure 5), indicating
that Tobramycin & Dex Eye Drops had the fastest toxicity
effect,  followed  by  Diclofenac  Sodium  Eye  Drops,
Pranoprofen Eye Drops, and Bromfenac Sodium Hydrate Eye
Drops.
According to cell proliferation, damage, and cell viability
assay, Bromfenac Sodium Hydrate Eye Drops had the least
significant  corneal  epithelial  effects  whereas  Diclofenac
Sodium Eye Drops had the most significant corneal epithelial
effects  among  the  four  anti-inflammatory  eye  drops.
Tobramycin & Dex Eye Drops showed the most significant
influence on cell migration and acute cytotoxicity.
Comparison of corneal epithelial effects among the active
components of anti-inflammatory eye drops: MTT and LDH
assays were used to evaluate the cytotoxicity of the active
components of the four anti-inflammatory eye drops. HCECs
were incubated with 0.010%, 0.020%, 0.050%, and 0.100%
(the same concentrations as the original eye drops) active
component solutions for 24 h. The corneal epithelial toxicity
differences among the active components of the four eye drops
became  significant  as  the  concentration  increased  above
0.020%. Only diclofenac and bromfenac components showed
significant cytotoxicity at the higher concentrations (0.050%
and 0.100%; Figure 6).
Comparison  of  corneal  epithelial  effects  between  anti-
inflammatory  eye  drops  and  their  active  components:  To
confirm the cytotoxic origin, MTT and LDH assays were used
to  evaluate  the  differences  between  the  four  anti-
inflammatory  eye  drops  and  their  corresponding  active
components  at  the  0.010%  concentration  (Figure  7).  The
active  component  groups  showed  no  cytotoxicity  toward
HCECs  compared  with  the  control  group.  The  four  anti-
inflammatory eye drops showed significant toxicity on the
proliferation and damage of HCECs when compared with the
control and the active components. The cellular toxicity of the
four anti-inflammatory eye drops did not originate from the
active  components  but  from  the  preservatives  or  other
ingredients.
DISCUSSION
Ocular epithelial disorders after eye surgery can result in
visual deterioration and patient discomfort, which may be
caused  by  drug  toxicity.  In  the  present  study,  we
systematically evaluated the overall cellular effects of four
commercially available anti-inflammatory eye drops and their
active components on HCECs in vitro. The results indicated
that Diclofenac Sodium Eye Drops (contains 0.1% diclofenac
sodium)  showed  significant  effects  on  cell  damage  and
viability, which was consistent with previous reports [7,11,
12].  The  cytotoxicity  of  diclofenac  was  represented  by
retarding corneal epithelial healing [8,13], decreasing cell
growth [14], and causing the higher incidence of persistent
epithelial defects [15]. The mechanism related with diclofenac
not only blocks the COX pathway but also diminishes the pool
Figure 5. The LT50 of the four anti-
inflammatory eye drops. HCECs were
treated  directly  with  100-μl  undiluted
eye  drops  and  stopped  by  10-mL
DMEM/F-12  media  (n=4).  The  cells
were labeled with 7-AAD staining, and
the cell viability was measured using
flow cytometry. The LT50 was counted
according to the cell viability curve. The
LT50  was  23.80  min  for  Bromfenac
Sodium Hydrate Eye Drops, 10.38 min
for Pranoprofen Eye Drops, 9.23 min for
Diclofenac Sodium Eye Drops, and 3.28
min for Tobramycin & Dex Eye Drops.
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3152of  available  arachidonic  acid.  Arachidonic  acid  is  an
important component of cellular structural integrity; the lack
of its availability and the potentially increased permeability
of cellular membranes may lead to corneal epithelial cell death
and  keratolysis  [16,17].  It  should  be  mentioned  that
Tobramycin & Dex Eye Drops inhibited the migration and
showed  the  quickest  effect  on  cell  viability  in  the  study.
However, the inhibitory effect on corneal epithelial migration
was related with Dex, and the inhibition of cell viability was
caused  by  the  presence  of  Tobramycin,  according  to  our
previous study (data not shown).
It  should  be  mentioned  that  there  were  significant
differences between acute and chronic cellular effects among
these  four  anti-inflammatory  eye  drops.  As  previous
description,  steroid  levels  in  the  cornea  decrease  by  50%
within 1 h after topical application [18], while the aqueous
humor  concentrations  of  topically  applied  Diclofenac  and
Bromfenac gradually decreased until complete removal after
approximately 24 h because of the rapid turnover of tear,
aqueous humor, etc. [19,20]. However, the concentrations of
eye drops exposed to human corneal epithelial cells in vitro
remained  constant,  which  represents  the  early  higher
concentrations when topical application in vivo. For these
reasons, the 24 h exposure of cultured epithelial cells to eye
drops in the present study was parallel with the long-term
exposure time and concentration experienced by epithelial
cells  in  vivo.  Moreover,  the  HCECs  showed  significant
toxicity when exposed to the constant concentrations of eye
Figure  6.  Effects  of  the  active
components  of  the  four  anti-
inflammatory  eye  drops  on  cultured
HCECs.  HCECs  were  treated  with
0.010%, 0.020%, 0.050%, and 0.100%
solutions for 24 h (n=4) and analyzed by
MTT  assay  (A)  and  LDH  assay  (B).
Only  diclofenac  and  bromfenac
components  showed  significant
cytotoxicity at the concentrations above
0.020% and 0.100%.
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3153drops in vitro, so we measured the acute cellular toxicity
within 1 h, while measured the chronic cellular toxicity within
24 h. More importantly, we first found significant differences
between the eye drops and their active components under the
0.010% concentration, but we did not find any differences
among their active components at the same concentrations.
Moreover, the pH values of 0.001%, 0.002%, and 0.010% eye
drops diluted in cell culture media became almost identical
(data not shown). The above results suggest that the corneal
epithelial toxicity of the four anti-inflammatory eye drops
were independent in their active components or pH values,
especially in the lower concentrations (<0.010%).
As  reported  previously,  preservatives  and  buffering
agents are essential ingredients except of active components
in eye drops. They provide a level of antimicrobial activity
and  prolong  the  half-life  of  the  drug  by  preventing
biodegradation and maintaining drug potency [21]. However,
long-term topical use may cause tear film instability, loss of
goblet  cells,  ocular  epithelial  squamous  metaplasia  and
apoptosis,  disruption  of  corneal  epithelium  barrier,  and
Figure  7.  Comparisons  of  corneal
epithelial toxicity of anti-inflammatory
eye drops and their active components.
HCECs were treated with either 0.010%
eye drops or 0.010% active components
for 24 h (n=4). The corneal epithelial
toxicity was measured by MTT assay
(A)  and  LDH  assay  (B).  Significant
differences were between the eye drops
and  the  corresponding  active
components.
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3154damage to deeper ocular tissues. Therefore, care should be
taken to avoid long-term use of preservative-containing eye
drops or to use preservative-free solutions whenever possible.
Diclofenac  sodium  eye  drops  containing  thimerosal  from
Japan  or  Europe  caused  punctuating  corneal  epithelial
damage, whereas the USA products containing sorbic acid or
the  diclofenac  sodium  solution  alone  had  no  significant
toxicity.  Because  the  present  study  had  limited  product
information  about  the  components,  contents,  and  possible
interactions between the preservatives and other agents, it is
necessary to further investigate the origin of cellular toxicity.
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